In 2012, the US cardiac rhythm management (CRM) market was valued at approximately $6.8 billion.
The CRM market includes pacemakers, cardiac resynchronization therapy (CRT) devices, implantable cardioverter defibrillators (ICDs), cardiac stimulation leads, external defibrillators, ablation catheters, diagnostic electrophysiology (EP) catheters, intracardiac ultrasound (ICE) catheters, electrophysiology (EP) stimulators, diagnostic ECG and cardiac monitoring devices.
Cardiac dysrhythmia (also known as an irregular heartbeat) is any of a large and heterogeneous group of conditions in which there is abnormal electrical activity in the heart. The heartbeat may be too fast or too slow, and may be regular or irregular.
A heart beat that is too fast is called tachycardia and a heart beat that is too slow is called bradycardia.
The method of cardiac rhythm management depends firstly on whether or not the affected person is stable or unstable. Treatments may include physical maneuvers, medications, electricity conversion, or electro or cryo cautery.
The rising incidence of lifestyle diseases such as diabetes and obesity, an ageing population and the prevalence of cardiovascular diseases such as arrhythmias, heart failure and atrial fibrillation, have expanded the patient pool for CRM devices in the US.
The larger market, however, does not translate to higher revenues, as there is considerable pressure on manufacturers to reduce the cost of all pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) devices.
The primary culprit for the CRM market slump in the US remains the toxic mix of a US Dept. of Justice investigation into the hospitals ICD implant practices and a January 2011 study published in the Journal of the American Medical Assn. showed that 22.5% of patients fell short of medical guidelines required to receive the $25,000 devices.
CRM device manufacturers have managed to stay afloat in this market through continuous product upgrades and technological advancements. Companies that launch an innovative product that addresses end-user concerns will gain significant first-mover advantage.
Major players currently dominating the US cardiac rhythm management market include Boston Scientific, St. Jude Medical, and Medtronic Inc.
For more information on the US cardiac rhythm management market, see the latest research: US Cardiac Rhythm Management Market
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.